Skip to main content
BIAF
NASDAQ Industrial Applications And Services

bioAffinity Technologies Q2 2026: Going Concern Warning, Nasdaq Delisting Notice, Cash Runway Through August

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.51
Mkt Cap
$3.204M
52W Low
$0.507
52W High
$13.5
52W Position info
0.6% above low
Off High info
96% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

BIAF is trading near its 52-week low of $0.507 (0.6% above the low).

Summary

bioAffinity Technologies' Q2 2026 filing discloses a going concern warning, a Nasdaq delisting notice, and a cash runway that ends this month. CyPath Lung revenue is growing but losses are accelerating, and the company urgently needs new financing.


Key Events · Earnings and Guidance · BIAF

  • Going Concern Warning

    Management concludes substantial doubt about the company's ability to continue as a going concern. Cash of $2.4M at June 30, 2026, is only sufficient to fund operations through August 2026.

  • Nasdaq Delisting Notice

    Received July 30, 2026, for failing the $1 minimum bid price rule. The company has requested a hearing appeal, staying any delisting action pending the panel's decision.

  • Q2 2026 Financial Results

    Net loss of $3.4M for Q2, $7.0M for H1 2026. Revenue of $1.5M for Q2, up 19% YoY, driven by CyPath Lung growth, but operating expenses rose 28% to $4.8M.

  • CyPath Lung Revenue Growth

    CyPath Lung testing revenue increased 159% to $835K in H1 2026 vs $323K in H1 2025. Unit sales grew 216% in Q2, with 1,100 tests delivered in H1.


Analysis · BIAF · Industrial Applications And Services

bioAffinity Technologies' Q2 2026 10-Q reveals a critical liquidity crisis. With only $2.4 million in cash at June 30 and a burn rate that depletes funds by August 2026, management has issued a going concern warning. The company also received a Nasdaq delisting notice for failing the $1 minimum bid price rule, adding listing risk to the financial distress. While CyPath Lung revenue grew 159% year-over-year to $835,000 in the first half, it is nowhere near enough to offset a $7 million net loss. The company raised $3.2 million in June but needs immediate additional capital to survive. The stock trades near its 52-week low of $0.51, reflecting the market's assessment of these existential risks.

At the time of this filing, BIAF was trading at $0.51 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.51 to $13.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIAF - Latest Insights

BIAF
Aug 07, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5201
Real-time Price: $0.5098 info
Change: -$0.0103 (-2%) info
Market Cap: $3.204M info
BIAF
Aug 07, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.5289
Real-time Price: $0.5098 info
Change: -$0.0191 (-4%) info
Market Cap: $3.204M info
BIAF
Jul 31, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5986
Real-time Price: $0.5098 info
Change: -$0.0888 (-15%) info
Market Cap: $3.204M info
BIAF
Jul 07, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8401
Real-time Price: $0.5098 info
Change: -$0.3303 (-39%) info
Market Cap: $3.204M info
BIAF
Jul 07, 2026, 8:54 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8355
Real-time Price: $0.5098 info
Change: -$0.3257 (-39%) info
Market Cap: $3.204M info